Pulse Biosciences, Inc Common Stock (DE) PLSE
i
Market dataready · fetched 2026-11-12T15:29:15.270Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:26:30.576445499Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T15:29:14.885135+00:00
Pulse Biosciences, Inc Common Stock (DE) options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 42.79 | 228.5% | 25.0% | |||
| 25Δ | 73.57 | 241.5% | 41.3% | 46.60 | 177.4% | 18.0% |
| 30Δ | 59.34 | 103.9% | 13.1% | 49.14 | 143.6% | 13.2% |
| 35Δ | 58.28 | 101.9% | 11.9% | 50.23 | 128.9% | 11.3% |
| 40Δ | 57.22 | 99.9% | 10.6% | 51.32 | 114.2% | 9.4% |
| 45Δ | 56.16 | 97.9% | 9.4% | 52.42 | 99.5% | 7.4% |
| 50Δ | 55.10 | 95.9% | 8.2% | 53.51 | 84.8% | 5.5% |
| 55Δ | 54.05 | 93.9% | 6.9% | 54.61 | 70.1% | 3.5% |
| 60Δ | 52.99 | 91.8% | 5.7% | 55.59 | 65.4% | 2.6% |
| 65Δ | 51.93 | 89.8% | 4.5% | 56.52 | 66.5% | 2.2% |
| 70Δ | 50.87 | 87.8% | 3.2% | 57.45 | 67.6% | 1.8% |
| 75Δ | 49.72 | 88.3% | 2.2% | 58.38 | 68.7% | 1.4% |
| 80Δ | 47.75 | 107.0% | 2.0% | 59.31 | 69.7% | 1.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 42.79
- IV
- 228.5%
- B/E move
- 25.0%
25Δ
- Pseudo strike
- 73.57
- IV
- 241.5%
- B/E move
- 41.3%
- Pseudo strike
- 46.60
- IV
- 177.4%
- B/E move
- 18.0%
30Δ
- Pseudo strike
- 59.34
- IV
- 103.9%
- B/E move
- 13.1%
- Pseudo strike
- 49.14
- IV
- 143.6%
- B/E move
- 13.2%
35Δ
- Pseudo strike
- 58.28
- IV
- 101.9%
- B/E move
- 11.9%
- Pseudo strike
- 50.23
- IV
- 128.9%
- B/E move
- 11.3%
40Δ
- Pseudo strike
- 57.22
- IV
- 99.9%
- B/E move
- 10.6%
- Pseudo strike
- 51.32
- IV
- 114.2%
- B/E move
- 9.4%
45Δ
- Pseudo strike
- 56.16
- IV
- 97.9%
- B/E move
- 9.4%
- Pseudo strike
- 52.42
- IV
- 99.5%
- B/E move
- 7.4%
50Δ
- Pseudo strike
- 55.10
- IV
- 95.9%
- B/E move
- 8.2%
- Pseudo strike
- 53.51
- IV
- 84.8%
- B/E move
- 5.5%
55Δ
- Pseudo strike
- 54.05
- IV
- 93.9%
- B/E move
- 6.9%
- Pseudo strike
- 54.61
- IV
- 70.1%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 52.99
- IV
- 91.8%
- B/E move
- 5.7%
- Pseudo strike
- 55.59
- IV
- 65.4%
- B/E move
- 2.6%
65Δ
- Pseudo strike
- 51.93
- IV
- 89.8%
- B/E move
- 4.5%
- Pseudo strike
- 56.52
- IV
- 66.5%
- B/E move
- 2.2%
70Δ
- Pseudo strike
- 50.87
- IV
- 87.8%
- B/E move
- 3.2%
- Pseudo strike
- 57.45
- IV
- 67.6%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 49.72
- IV
- 88.3%
- B/E move
- 2.2%
- Pseudo strike
- 58.38
- IV
- 68.7%
- B/E move
- 1.4%
80Δ
- Pseudo strike
- 47.75
- IV
- 107.0%
- B/E move
- 2.0%
- Pseudo strike
- 59.31
- IV
- 69.7%
- B/E move
- 1.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.30% | |
| 67.11% | |
| 66.88% | |
| 66.48% | |
| 67.45% | |
| 67.85% | |
| 68.64% | |
| 68.06% | |
| 68.55% | |
| 68.90% |
Medical Instruments & Supplies
RGEN
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and…
More →RMD
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices…
More →SOLV
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs.…
More →STAA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company…
More →STVN
Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in innovative glass and polymer packaging solutions designed for injectable…
More →STXS
Description unavailable
More →